+82.7%
MRVL vs GSK
+14.9%
+67.8%
-49.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -7.1% | +5.0% | -12.1% | -5.4% |
| 7D | -36.5% | +4.9% | -41.4% | -35.3% |
| 30D | -41.1% | +9.9% | -51.0% | -39.2% |
| 3M | -26.9% | +0.2% | -27.0% | -25.6% |
| 6M | -2.3% | +2.3% | -4.6% | -1.0% |
| YTD | +88.4% | +7.1% | +81.3% | +91.3% |
| 1Y | +82.7% | +13.1% | +69.6% | +83.2% |
| All | +82.7% | +14.9% | +67.8% | +83.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling